INTRODUCTION
Psoriasis and psoriatic arthritis (PsA) are common conditions that have a significant impact on affected patients. The availability of novel and expensive therapeutic agents for both psoriasis and PsA, such as "biologics", has generated considerable interest in clinical trials. Therefore, there is a great need for standardized outcome measures to evaluate the activity of the diseases mentioned above as well as their response to therapy. To date, different tools have been developed for such purposes, the most popular ones will be analyzed below.
PSORIASIS ASSESSMENT TOOLS
The Psoriasis Area Severity Index (PASI) (1) is currently the most popular tool in clinical studies. It is a measure of the average redness, thickness, and scaliness of the lesions (each graded on a 0-4 scale), weighed by the area of involvement (Tab. I). The final result of this method of assessment ranges from 0.0 to 72.0. In most clinical trials a ≥75% reduction from baseline PASI scores (PASI 75) is the benchmark of primary endpoints in assessing therapies for psoriasis (2) . However, PASI 75 has been considered too stringent by Carlin CS and coworkers (3) . In fact, these authors published data indicating that a PASI reduction ≥50 (PASI 50) demonstrates a clinically meaningful improvement and represents an appropriate primary endpoint for clinical trials. The main limitations of the PASI score are: 1) no discrimination when low body surface areas of involvement are present; 2) upper end of scale is only theoric (2).
The Physician Global Assessment (PGA) (4) is another widely used system employed in psoriasis clinical trials. In its typical formulation, it is a 7-point scale ranging from clear to severe (Tab. II). In most versions of the PGA, the individual elements of psoriasis plaque morphology or degree of body surface area involvement are not quantified. Although PGA has the advantage to evaluate disease severity in a more intuitive way than the 0 to 72 score of PASI, it presents different limitations, for example: 1) various PGAs have been utilized with different descriptions and scores making it more difficult to compare data among different clinical trials; 2) it does not discriminate small changes; 3) range not robust (2) .
The National Psoriasis Fundation-Psoriasis Score (NPF-PS) (5) is a responder index that encompasses different subdomains: 1) induration at two target sites; 2) current and baseline body surface area;
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Table I -Elements of the Psoriasis Area and Severity Index (PASI).
Head
Upper extremities Trunk Lower extremities To help improve intra-rater and inter-rater reliability of the induration score, the NPF-PS utilizes a reference card embossed with elevations that increase at 0.25 mm intervals. This composite index presents a number of advantages such as:
Tabella III -Elements of National Psoriasis Foundation Psoriasis Score (NPF-PS).
Score
1) correlation with Dermatology Life Quality Index; 2) a good discrimination when body surface area is low; 3) patient input is considered; 4) thickness is predominate component; 5) all elements are defined. However, the NPF-PS is time consuming, has not been widely tested and has not yet been accepted by approving agencies nor clinicians.
The Dermatology Life Quality Index (DLQI) (6) is the most widely used measure for assessing quality of life related to skin disease in psoriasis trials (2) . This tool consists of 10 questions covering six domains (symptoms and feelings, daily activities, leisure, work and school, personal relationships, and trouble with psoriasis treatment). The response options range from 0, not affected at all, to 3, very much affected. This gives an overall range of 0-30 where lower scores mean better quality of life. The reliability, construct validity, and sensitivity to change of the DLQI have all been demonstrated in psoriasis patients (7).
PSA ASSESSMENT TOOLS
The American College Rheumatology (ACR) response criteria, initially developed for Reumatoid Arthritis clinical trials (8), is an outcome measure of PsA, which requires improvement in: 1) tender joint count; 2) swollen joint count; 3) 3 of 5 addi tional measures, which include patient global assessment of disease activity, physician global assessment of disease activity, patient assessment of pain, functional status (e.g. using the Healt Assessment Questionnare, 9) and an acute phase reactant.
The origi nal criteria, commonly called the ACR 20 (Tab. IV), require 20% improvement in these measures (8); a more extensive improve ment may be documented according to ACR50 and ACR70, which require 50% and 70% improvement, respec tively. ACR20 criteria are reported to be as effective as higher levels to dis tinguish active treatment from placebo responses (10) , and have been widely used as a primary outcome measure in clinical trials in PsA with good perfor mance (11) . Psoriatic Arthritis Response Crite ria (PsARC) is a tool specifically develop ed for a study to evaluate the efficacy of sulfasalazine in PsA (12) . Th e PsARC is composed of four measures, including: 1) patient global assessment of disease activity (improvement of 1 on a 5 point Likert scale is required for a response; 2) physician global assess ment of disease activity (improvement of 1 on a 5 point Likert scale is required for a response); 3) joint pain (reduction of 30% or more in total score, assessing either 68 or 78 joints, requiring a 4 point scale for a response), and iv) joint swelling (reduction of 30% or more in total score, assessing either 66 or 76 joints, requiring a 4 point scoring scale for a response) (Tab. V).
In or der to be a 'PsARC responder', pa tients must achieve improvement in 2 of 4 measures, one of which must be joint pain or swelling, without worsen ing in any measure. In several trials of various therapeutic agents where it was 
